| Literature DB >> 32000802 |
Daixi Ren1,2,3, Yuze Hua1,2,3, Boyao Yu1,2,3, Xin Ye2, Ziheng He2, Chunwei Li2, Jie Wang2, Yongzhen Mo2, Xiaoxu Wei2, Yunhua Chen2, Yujuan Zhou1, Qianjin Liao1, Hui Wang1, Bo Xiang1,2,3, Ming Zhou1,2,3, Xiaoling Li1,2,3, Guiyuan Li1,2,3, Yong Li4, Zhaoyang Zeng1,2,3, Wei Xiong5,6,7.
Abstract
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a variety of tumors, but resistance during treatment is a major issue. In this review, we describe the utility of PD-L1 expression levels, mutation burden, immune cell infiltration, and immune cell function for predicting the efficacy of PD-1/PD-L1 blockade therapy. Furthermore, we explore the mechanisms underlying immunotherapy resistance caused by PD-L1 expression on tumor cells, T cell dysfunction, and T cell exhaustion. Based on these mechanisms, we propose combination therapeutic strategies. We emphasize the importance of patient-specific treatment plans to reduce the economic burden and prolong the life of patients. The predictive indicators, resistance mechanisms, and combination therapies described in this review provide a basis for improved precision medicine.Entities:
Keywords: Cancer immunotherapy; Immune cells; Immune checkpoint blockade; PD-1/PD-L1; Precision medicine
Mesh：
Substances：
Year: 2020 PMID： 32000802 PMCID： PMC6993488 DOI： 10.1186/s12943-020-1144-6
Source DB: PubMed Journal: Mol Cancer ISSN： 1476-4598 Impact factor: 27.401